Friend murine erythroleukemia (MEL) cells are transformed erythroid precursors that are held in an immature and proliferating state but can be induced to dierentiate in vivo by treatment with a variety of chemical agents such as N, N-hexamethylene bisacetamide (HMBA). To investigate the role of Myb proteins in maintaining MEL cells in an immature and proliferating state we have produced stable transfectants in the C19 MEL cell line that contain a dominant interfering Myb allele (MEnT) under the control of an inducible mouse metallothionein I promoter. When expression of MEnT protein was induced with ZnCl 2 , the stable transfectants dierentiated with kinetics that were similar to wild type C19 MEL cells treated with HMBA, including induction of aglobin mRNA expression, assembly of hemoglobin and growth arrest. Expression of endogenous c-myb and cmyc was also decreased in response to MEnT. Expression of mad-1 mRNA was rapidly increased in response to expression of MEnT resulting in a shift from predominantly c-Myc/Max complexes to predominantly Mad/Max containing complexes. These results strongly suggest that C19 MEL cells are held in an immature and proliferating state by a pathway that is dependent on Myb activity.
Introduction
The c-myb protooncogene is the cellular homologue of the transforming v-myb genes identi®ed in avian myeloblastosis virus (AMV) and avian leukemia virus (E26) and is essential for development of the hematopoietic system (Graf, 1992) . c-myb encodes a transcription factor that binds DNA in a sequencespeci®c manner and regulates gene expression (Lipsick, 1996) . To date, potential c-myb target genes include genes associated with cell proliferation and survival as well as genes that are expressed in hematopoietic cells in a lineage-speci®c fashion (Oh and Reddy, 1999) . The c-Myb DNA-binding domain has been highly conserved through evolution and de®nes a large family of proteins in eukaryotes (Lipsick, 1996) . However, in vertebrates, only two proteins, A-Myb and B-Myb, have signi®cant homology with c-Myb outside of the DNA-binding domain (Nomura et al., 1988; Lipsick, 1996) . While all three Myb proteins can bind the consensus c-Myb DNAbinding sequence, they have distinct tissue and cell type patterns of expression. A-myb is highly expressed in male germ cells, female breast ductal epithelium and subsets of B lymphocytes (Golay et al., 1996 (Golay et al., , 1998 Trauth et al., 1994) , while B-myb expression appears to be nearly ubiquitous (Golay et al., 1991; Nomura et al., 1988; Reiss et al., 1991) . Expression of c-myb is predominantly detected in normal tissue and tumor cells of hematopoietic origin although a broader range of expression has been reported during embryonic development and in adult hair follicles and gastrointestinal crypt epithelial cells (Ess et al., 1999; Westin et al., 1982) . The down regulation of c-myb expression is associated with hematopoietic maturation, and in each hematopoietic lineage examined the expression of c-myb mRNA and protein is highest in immature normal tissue and tumor cell lines (Graf, 1992) . This expression pattern suggests that c-myb plays an important role in hematopoietic maturation, which is strongly supported by the embryonic lethality of c-myb de®cient mice that die at embryonic day 15 due to severe anemia (Mucenski et al., 1991) . In addition, transgenic mice that express a dominant interfering myb allele in a tissue-speci®c manner have small thymuses, disrupted T cell dierentiation and poor mature T cell proliferation (Badiani et al., 1994) . More recently, using homozygous null c-Myb/Rag1 chimeric mice, Allen et al. (1999) demonstrated that c-Myb plays an important role in the dierentiation of macrophages and lymphocytes from precursor stem cells and is required at an early stage of T cell development.
Several leukemic models provide useful systems to study the function of Myb activity in regulating proliferation and dierentiation (Bies et al., 1996; Clarke et al., 1988; Gonda and Metcalf, 1984; Lyon and Watson, 1995; McClinton et al., 1990; Oh and Reddy, 1999; Yen et al., 1992) . Murine erythroleukemia (MEL) cell lines are transformed erythroid precursor cells arrested in development at approximately the proerythroblast stage (Friend et al., 1971) . MEL cells are derived from mice that have been infected with the Friend virus complex, which is composed of two dierent entities, replication-defective spleen focus-forming virus (SFFV) and the replicationcompetent Friend murine leukemia virus (F-MuLV) (Ben-David et al., 1991) . The initial phase of the disease induced by the Friend virus complex is a polyclonal expansion of erythroblasts, that are still able to dierentiate, due to constitutive activation of the erythropoietin (Epo) receptor mediated by its physical interaction with the gp55 env glycoprotein encoded by SFFV (Casadevall et al., 1991; Li et al., 1990) . After several weeks of infection, erythroleukemia cells of clonal origin begin to emerge that have unlimited selfrenewal capacities and do not dierentiate. Most MEL cell lines established from this second step contain SFFV proviral integration at the Spi-1 locus, resulting in transcriptional activation of the ETS family transcription factor PU.1/Spi1-1 (Moreau- Gachelin et al., 1988 Gachelin et al., , 1989 . When stimulated with chemical agents such as DMSO or HMBA, MEL cells respond by activating a program that leads to terminal dierentiation, which includes growth arrest, accumulation of globin mRNA and assembly of hemoglobin (Marks and Rifkind, 1978) . Thus, MEL cells provide a useful in vivo model system for examining aspects of multistep transformation and erythroid dierentiation.
Expression of several proto-oncogenes, including PU.1, c-myb, and c-myc are down regulated when MEL cells are induced to dierentiate with HMBA or DMSO (Craig and Bloch, 1984; Duprey and Boettiger, 1985; Gonda and Metcalf, 1984; Lachman et al., 1986; Ramsay et al., 1986; Rao et al., 1997) . Upon exposure to chemical inducing agents, expression of c-myb and cmyc mRNA rapidly declines and then is re-expressed to nearly pretreatment levels by about 24 h post-induction, followed by a second gradual decline as MEL cells undergo terminal dierentiation Ramsay et al., 1986) . The signi®cance of downregulating expression of these genes has been demonstrated by reports from several groups that forced expression of either c-myb, c-myc or PU-1 in MEL cells blocks the chemically induced dierentiation (Rao et al., 1997; Dmitrovsky et al., 1986; McClinton et al., 1990; Clarke et al., 1988; Todokoro et al., 1988) and it has been suggested that MEL cell dierentiation requires a series of steps involving down regulation of protooncogene expression in the order PU.1?cmyb?c-myc (Rao et al., 1997) .
To determine if a Myb regulated pathway is limiting for dierentiation in MEL cells, we have made stable transfectants in the C19 MEL cell line that contain a dominant interfering Myb transgene under the transcriptional control of the mouse metallothionein I promoter. The dominant interfering Myb protein (MEnT) consists of a truncated c-Myb DNA binding domain fused to a portion of the Drosophila engrailed transcription repressor (Badiani et al., 1994) . When expression of MEnT is induced by treating transfected MEL cells with ZnCl 2 , the stable transfectants dierentiate with kinetics that are similar to those of wild type C19 MEL cells induced to dierentiate with HMBA. MEnT induced dierentiation includes induction of a-globin mRNA expression and assembly of hemoglobin as well as growth arrest in the G1-phase of the cell cycle. In addition, we found that expression of cmyc and mad-1 mRNA and protein was regulated in a reciprocal manner during MEnT induced dierentiation of MEL cells, resulting in a shift from predominantly cMyc/Max complexes to Mad/Max complexes. These results strongly suggest that C19 MEL cells are held in a proliferating and undierentiated state by a pathway that is dependent on Myb activity.
Results

Inducible expression of a dominant interfering c-Myb protein in C19 MEL cells
To determine if interfering with Myb activity provides a sucient stimulus to allow MEL cell dierentiation, we made stable transfectants in the C19 MEL cell line that contain a transgene encoding a dominant interfering Myb (MEnT) protein under the control of the mouse metallothionein I promoter (see Materials and methods). MEnT is a fusion protein that contains two functional domains: a truncated c-Myb DNA binding domain and the Drosophila engrailed transcription repressor domain (Badiani et al., 1994) . The MEnT protein binds DNA containing the consensus Myb binding sequence via the Myb DNA-binding domain and serves to actively repress transcription (Badiani et al., 1994) . In addition, MEnT has a carboxyl-terminal c-Myc epitope tag for detection of the fusion protein. Stable transfectants were also made that produce only the engrailed transcription repressor domain (EnT) under the control of the mouse metallothionein I promoter, or contain the empty pMTH.neo vector. Figure 1 presents an immunoblot of protein extracts from cloned C19 MEL cell lines transfected with pMTH.MEnT, pMTH.EnT or pMTH.neo that were probed with the 9E10 mAb. In the three MEnT producing clones and two EnT producing clones, proteins of the expected sizes were detected after treatment with ZnCl 2 , while in the empty vector (EV) control clone the 9E10 mAb did not react with any proteins. In addition, MEnT could be detected by probing the ®lters with an anti-Myb DNA binding domain mAb (see Figure 4 for example). In each clone, MEnT was detected only when C19 MEL cells transfected with pMTH.MEnT were treated with ZnCl 2 . However, after several months in culture, a low background of MEnT expression was detected in these transfectants, likely due to leakiness of the metallothionein promoter (see Figure 4b for example).
MEnT induces expression of a-globin mRNA and production of hemoglobin in C19 MEL cells
To determine if inhibition of Myb activity by MEnT induced C19 MEL cells to produce increased amounts of a-globin mRNA and assemble hemoglobin, the pMTH.MEnT stable transfectant clone 14 was treated with 100 mM ZnCl 2 for 5 days and compared with C19 MEL cells treated with HMBA for the same amount of time. As presented in Figure 2a , logarithmically growing C19 MEL cells produced little a-globin mRNA in the absence of HMBA, but expression of a-globin mRNA was readily detectable 24 h following HMBA treatment and increased over the 5 day time course. Similar to C19 MEL cells, clone 14 cells produced little a-globin mRNA. However, after treatment with 100 mM ZnCl 2 for 24 h, clone 14 cells produced increasing amounts of a-globin mRNA throughout the 5 day course of the experiment. We note that more a-globin mRNA is detected in the clone 14 cell line prior to treatment with ZnCl 2 than in the parental C19 MEL cell line. As described above, after several months in culture we started to detect a small amount of breakthrough MEnT expression that is due to the leakiness of the mouse metallothionein I promoter (see Figure 4b for example). Interestingly, the amount of a-globin mRNA produced in the clone 14 cell line was several fold greater by 24 ± 48 h of treatment with 100 mM ZnCl 2 than the amount detected in the parental C19 cell line after treatment with HMBA. This was true for all three of the MEnT transfected cell lines that we have characterized in detail. However, both parental C19 and MEnT transfected cell lines produced similar amounts of aglobin mRNA by 72 h post induction. This result suggests that Myb activity may normally be involved in maintaining C19 MEL cells in a condition where aglobin mRNA expression is suppressed.
To determine if MEnT stable transfectants were able to assemble hemoglobin after treatment with 100 mM ZnCl 2 , we measured hemoglobin production in single cells using the acid benzidine staining assay. Figure 2b presents results of acid benzidine staining for both C19 MEL cells (Figure 2b upper panels) and clone 14 cells (Figure 2b lower panels) treated with or without HMBA or ZnCl 2 respectively for 3 days. In the absence of HMBA, C19 MEL cells did not synthesize detectable amounts of hemoglobin as measured by this assay, but after treatment with HMBA for 3 days, approximately 50% of C19 MEL cells stained benzidine positive. Similarly, in the absence of ZnCl 2 , few clone 14 cells stained as benzidine positive (less than 1 in 500). However, after treatment with 100 mM ZnCl 2 for 3 days to induce expression of MEnT, approximately 50% of the clone 14 cells were benzidine positive. It is important to note that the EnT stable transfectants did not stain benzidine positive, nor did they make a-globin mRNA in response to treatment with 100 mM ZnCl 2 (see Figure 2c and below). However, EnT stable transfectants did retain the ability to dierentiate in response to HMBA as measured by hemoglobin production. Thus, interfering with Myb activity provides a sucient stimulus to induce transcription of a-globin mRNA and assembly of hemoglobin in C19 MEL cells.
The appearance of benzidine positive in clone 14 cells treated with ZnCl 2 was further compared to C19 MEL cells treated with HMBA over a 5 day time course to examine the kinetics of hemoglobin production. As presented in Figure 2c , C19 MEL cells did not begin to synthesize detectable amounts of hemoglobin until 24 ± 48 h post treatment with HMBA, after which time the number of acid benzidine positive cells steadily increased and reached a maximum of approximately 85% by day ®ve. Treatment of the parental C19 MEL cell line with ZnCl 2 did not induce the appearance of hemoglobin producing cells. Clone 14 cells responded quickly to treatment with ZnCl 2 , and by 24 h post treatment, 5% of the cells became benzidine positive. This result is in contrast to the C19 parent cell line, where no acid benzidine positive cells were detected by 24 h after treatment with HMBA, and is consistent with the more rapid accumulation of a-globin mRNA in clone 14 cells than in C19 MEL cells (see Figure 2a ). The number of acid benzidine positive cells in clone 14 increased to 50% by 72 h post treatment with ZnCl 2 and reached a maximum of approximately 60% by 5 days posttreatment. The kinetics of acid benzidine positive cell appearance in MEnT stable transfectants was similar in ®ve independent cloned cell lines, although the maximum number of acid benzidine positive cells at 5 days post treatment with 100 mM ZnCl 2 varied from 60 Figure 1 Inducible expression of MEnT and EnT proteins in C19 MEL cell stable transfectants. C19 MEL cells or C19 stable transfectants were grown in culture with or without 100 mM ZnCl 2 for 16 h. Cells were harvested and lysed with YRIPA buer. One hundred micrograms of total cell lysate from each clone were fractionated by SDS ± PAGE, transferred to nitrocellulose membranes and analysed by immunoblotting with the 9E10 anti-human c-Myc mAb. The EV1 clone was transfected with the empty vector control pMTH.neo, MEnT clones 14, 17, and 30 were transfected with pMTH.MEnT, and the EnT3 and EnT8 clones were transfected with pMTH.EnT to nearly 80% depending on the clone assayed. Importantly, EnT stable transfectants did not produce hemoglobin in response to treatment with 100 mM ZnCl 2 but retained the ability to dierentiate in response to HMBA (Figure 2c ). The lack of hemoglobin production in the EnT stable transfectants or the empty vector transfected MEL cells treated either with or without 100 mM ZnCl 2 demonstrates that the engrailed moiety of the MEnT protein functioned solely through the Myb DNA-binding domain. These results strongly support the notion that Myb activity is limiting for dierentiation in C19 MEL cells and that interfering with endogenous Myb activity is sucient to induce the MEL cells to dierentiate. 
Inhibition of Myb activity in C19 MEL cells leads to growth arrest
When MEL cells are induced to terminally dierentiate with HMBA, they decrease proliferation and arrest in the G1-phase of the cell cycle prior to terminal dierentiation (Marks et al., 1996) . As Myb proteins have been proposed to be required for cell cycle progression, we investigated the eect of MEnT induction on cell proliferation (Badiani et al., 1994; Gewirtz et al., 1989; Lyon and Watson, 1996; Saville and Watson, 1998) . We ®rst compared rates of proliferation between the parental C19 MEL cells treated with HMBA and clone 14 cells treated with ZnCl 2 (Figure 3a) . C19 MEL cells or clone 14 cells were seeded in duplicate at a density of 10 5 viable cells per ml at day zero and viable cell numbers were subsequently determined every 24 h over a 5 day time course. Both C19 MEL cells and clone 14 cells proliferated in a logarithmic fashion although the parental C19 MEL cells proliferated at a faster rate than clone 14. The doubling time for each cell cycle in parental C19 MEL cells was 10 h, while the doubling time for clone 14 cells was 16 h. Similar results were obtained for three other independent MEnT stable transfectants. The dierence in rate of proliferation was likely due to leakiness of the mouse metallothionein promoter, resulting in a small amount of MEnT protein being made in the absence of ZnCl 2 . When C19 MEL cells were treated with HMBA over a 5 day time course, the cells continued to proliferate in a logarithmic fashion for the ®rst 2 days after which proliferation began to slow down and appeared to reach a plateau of little or no proliferation by 3 days post treatment. In the case of clone 14 cells treated with 100 mM ZnCl 2 , the rate of proliferation appeared to decrease by day 1 of treatment and continued to decrease until it reached a plateau of essentially no proliferation after day 2. Clone 14 cells only completed three to four rounds of division over the 5 day time course in the presence of 100 mM ZnCl 2 . Treatment with ZnCl 2 did not eect the proliferation of parental C19 MEL cells, C19 MEL cells transfected with empty vector or EnT stable transfectants (data not shown).
The ®nding that MEnT expression resulted in decreased proliferation raised the possibility that simply inhibiting proliferation in MEL cells might provide a sucient stimulus for dierentiation. To address this question we examined proliferation and hemoglobin production in parental C19 MEL cells and clone 14 cells grown in growth medium supplemented with 0.5% FBS for 5 days. We found that, while both cell lines stopped proliferating under these conditions, no increase in the number of benzidine positive cells in either C19 MEL cells or clone 14 cells was observed (data not shown). Thus, it is unlikely that Myb activity simply acts as a stimulus for proliferation in C19 MEL cells. Rather, Myb regulated genes may be involved both in maintaining a state of proliferation and actively suppressing dierentiation.
Decreased production of viable cells in clone 14 cells after treatment with 100 mM ZnCl 2 could be due to cell cycle arrest, increased cell death or both. To distinguish between these possibilities, we examined the DNA content of C19 MEL cells and clone 14 cells induced to dierentiate with HMBA and 100 mM respectively by¯ow cytometry. Approximately 10 6 cells of each type were harvested at 24-h intervals over a 5 day time course following treatment with inducing agents, stained with propidium iodide and subjected tō ow cytometry. The percentage of cells found in the G1 phase of the cell cycle was determined and the results are presented in Figure 3b . Untreated populations of C19 MEL cells and clone 14 cells contained approximately 46 and 48% of the cells in the G1 phase of the cell cycle respectively at day 0. This number stayed roughly constant over the ®rst 2 days of the time course. Subsequently, the number of C19 MEL cells in the G1 phase of the cell cycle increased to approximately 65% by day 4 post treatment with HMBA. Similarly, when 100 mM ZnCl 2 was added to clone 14 cells to induce MEnT expression, the number of cells in the G1 phase of cell cycle increased to approximately 68% by day 4. This result strongly supports the notion that Myb activity is required for continued proliferation of C19 MEL cells. Apoptosis does not appear to be a signi®cant factor in decreasing viable cell numbers in either C19 MEL cells treated with HMBA or clone 14 cells treated with 100 mM ZnCl 2 because fewer than 5% of either cell type were found to be undergoing apoptotic cell death as measured by sub 2N DNA content or assays to measure DNA fragmentation (data not shown). In addition, we found no change in the expression of Bcl-2 or Bcl-xl mRNA in either C19 MEL cells treated with HMBA or clone 14 cells treated with 100 mM ZnCl 2 (data not shown). Both Bcl-2 and Bcl-xl function as anti-apoptotic factors and Bcl-2 has recently been reported to be regulated by Myb family members (Frampton et al., 1996; Heckman et al., 2000; Taylor et al., 1996) . Thus, we conclude that the lower proliferation rate in C19 MEL cells induced to dierentiate by HMBA treatment or expression of MEnT is mainly due to arrest in the G1 phase of the cell cycle. (Figure 4a ). Subsequently, expression of cmyb and c-myc mRNA was again down-regulated over the next few days as previously described (Richon et al., 1989) . Similar to previous reports, mad1 mRNA expression was up regulated in a biphasic fashion in response to treatment with HMBA. In clone 14 cells cultured with ZnCl 2 , MEnT expression was signi®cantly increased at 4 h and remained elevated during the 5 day time course. Expression of endogenous c-myb mRNA was modestly down regulated in clone 14 cells after treatment with 100 mM ZnCl 2 but the decrease in expression was not as marked as in the case of HMBA treated parental C19 MEL cells. It should be noted that c-myb expression is down regulated in clone 14 cells in response to HMBA to the same extent as detected in parental cell line (data not shown). Thus, MEnT expression had only a modest eect on c-myb mRNA levels. As presented in Figure 4a , expression of c-myc mRNA was down regulated in clone 14 cells after treatment with 100 mM ZnCl 2 , consistent with previous reports that c-myc is a c-myb target gene (Cogswell et al., 1993; Zobel et al., 1992) . Both the kinetics and magnitude of c-myc down regulation were similar in clone 14 to that observed in the parental C19 MEL cell line. Interestingly, increased expression of mad1 mRNA was detected within 4 h of treating clone 14 cells with 100 mM ZnCl 2 . However, as opposed to the parental C19 cell line treated with HMBA, expression of mad1 mRNA continued to increase throughout the 5 day time course.
The changes in c-myb and c-myc mRNA expression were generally paralleled by changes in the expression of the corresponding proteins at the selected time points (Figure 4b ). However, we observed a pronounced induction of Mad1 protein expression in clone 14 cells after treatment with ZnCl 2 for 4 h, which appears to be greater than the corresponding increase in mad1 mRNA expression at the same time point. Mad1 protein expression decreased approximately twofold between 4 and 24 h after treatment with ZnCl 2 , then remained constant throughout the remainder of the time course. Expression of Max protein did not change throughout the 5-day time course in either C19 MEL cells or clone 14 cells.
To determine if the changes in c-Myc and Mad1 expression resulted in a shift in the content of c-Myc/ Max/Mad1 containing complexes, we immunoprecipitated Max containing complexes and then probed immunoblots with antibodies speci®c for the c-Myc, Max and Mad1 proteins. As presented in Figure 4c , Max containing complexes detected in both C19 MEL cells and clone 14 cells contained almost entirely c-Myc and Max prior to treatment with HMBA or ZnCl 2 . However, by 72 h after treating C19 MEL cells with HMBA or clone 14 cells with ZnCl 2 , the content of these complexes consisted almost entirely of Mad1 and Max. Thus, interfering with Myb activity in C19 MEL cells also results in a switch from predominantly cMyc/Max containing complexes to complexes containing mostly Mad1 and Max.
Discussion
We have examined the role of Myb activity in maintaining MEL cells in an immature and proliferating state. For this purpose, we constructed stable transfectants in C19 MEL cells that contain a dominant interfering Myb allele (MEnT) under the transcriptional control of the inducible mouse metallothionein I promoter. We found that interfering with Myb activity in these cells provided a sucient stimulus to induce dierentiation as de®ned by production of globin mRNA, assembly of hemoglobin and inhibition of proliferation. Interestingly, MEnT expression also led to the down regulation of c-myc expression and a concomitant increase in mad1 gene expression, which resulted in a switch from a cellular milieu containing predominantly c-Myc/Max complexes to Mad1/Max complexes. The dierentiation Terminal dierentiation consists of two processes: phenotypic dierentiation and terminal cell division. The former process controls development of the phenotypically mature cell type, while the latter ensures that the number of phenotypically mature cells is appropriately limited (Matushansky et al., 2000) . When MEnT expression is induced in C19 MEL cells, dierentiation proceeds in concert with decreased proliferation and reduction in the number of proliferating cells due predominantly to arrest in the G1 phase of the cell cycle and not apoptosis. However, proliferation arrest is clearly not sucient to induce dierentiation. We found that both C19 MEL cells and clone 14 cells cultured for a continuous 5 day period in low serum containing growth medium stopped proliferation and arrested in the G1 phase of the cell cycle. However, this growth arrest was not sucient to induce production of hemoglobin as measured by benzidine staining, supporting the notion that simply inducing growth arrest is not sucient to induce dierentiation. Similar ®ndings were reported in a study on the role of retinoblastoma protein (Rb) in terminal dierentiation of MEL cells where treatment with forskolin resulted in dephosphorylation of Rb and a block in the mid-G1 phase of the cell cycle, yet this was not sucient to induce dierentiation as measured by hemoglobin production (Zhuo et al., 1995) . On the other hand, the erythroid kruppel-like transcription factor (ELKF) is able to induce hemoglobin production in MEL cells but does not induce cell cycle arrest (Spadaccini et al., 1998) . In contrast to these examples, interfering with Myb activity using the MEnT protein provided a sucient stimulus to arrest cell growth and induce dierentiation. These data support the previous hypothesis that prolongation of G1 is a necessary but not sucient, condition for commitment of MEL cells to terminal dierentiation (Zhuo et al., 1995) .
Several previous reports have indicated that interfering with c-Myb activity can induce or alter dierentiation in MEL cells. Studies using antisense oligonucleotides suggested that interfering with c-Myb expression provided a sucient signal to induce production of hemoglobin although little eect was reported on cell growth (Chern et al., 1991) . Weber et al. (1990) identi®ed a truncated c-myb cDNA that encoded the c-Myb DNA-binding domain but lacked a transactivation domain in leukemic myeloid cells. Interestingly, forced expression of this protein in MEL cells was not able to induce dierentiation, but it did accelerate chemically induced dierentiation (Weber et al., 1990) . The dominant interfering Myb allele used in our work is targeted to DNA by a truncated c-Myb DNA-binding domain (Badiani et al., 1994) and we have demonstrated that the ability of the MEnT construct to induce dierentiation and inhibit proliferation in C19 MEL cells is dependent on the DNA-binding domain. A-Myb and B-Myb are highly homologous to c-Myb in the DNA-binding domain and they appear to bind similar consensus sequences. However, the eect of DNA sequences that¯ank Myb responsive elements (MRE) on the binding speci®cities of the vertebrate Myb family members has not yet been studied in detail and little is understood about what de®nes the regulation of a given gene by individual Myb family members. Thus, it is not possible to de®nitively distinguish between the roles of c-Myb, AMyb and B-Myb in this model system. A-Myb is not expressed in C19 MEL cells (J Chen and T Bender unpublished observation) and, since A-Myb de®cient mice do not have reported defects in erythropoiesis, it is unlikely that potential down regulation of A-Myb target promoters is involved in mediating dierentiation by MEnT in MEL cells. In contrast, B-Myb is expressed in MEL cells and prevents growth arrest associated with dierentiation in a myeloid leukemic model of dierentiation (Bies et al., 1996) , strongly suggesting that some aspects of the growth inhibition and induced dierentiation that we describe could be caused by interfering with the expression of B-Myb target genes. In addition, B-Myb null embryos die due to failure of cellular proliferation beyond a very early inner cell mass stage. Since essentially all vertebrate cells appear to contain B-Myb protein (including C19 MEL cells) a wide variety of cell types may require BMyb to proliferate. De®nition of the individual roles played by the Myb family in regulating MEL dierentiation will require de®nition and understanding of genes regulated by individual family members as well as cell lines that allow for conditional ablation of the individual family Myb family members.
Previous reports, including our own work, have provided evidence that c-myc functions downstream of c-myb in MEL cells (Clarke et al., 1988; McClinton et al., 1990) . For example, conditional overexpression of c-Myb prevents the down regulation of c-myc that occurs in MEL cells during HMBA or DMSO induced dierentiation (McClinton et al., 1990) . This conclusion is further supported by two observations related to the inhibition of Myb activity by MEnT. First, expression of MEnT leads to the down regulation of endogenous c-myc mRNA and protein expression in C19 MEL cells (see Figure 4) , suggesting that c-myc lies downstream of a Myb regulated pathway. Second, we have made stable, inducible MEnT transfectants in a previously described C19 MEL cell line that can no longer dierentiate in response to HMBA because it carries multiple copies of a human c-myc transgene (Dmitrovsky et al., 1986) . Although expression of mRNA from the endogenous c-myc locus was down regulated by MEnT expression in these stable transfectants, the ectopically expressed c-myc transgene was not aected (data not shown). Expression of MEnT in these c-myc stable transfectants was not able to induce dierentiation, indicating that MEnT could not overcome the c-Myc mediated block to dierentiation.
While several groups have provided evidence that the c-myc promoter is a direct target of c-Myb activity this point has been controversial (Cogswell et al., 1993; Hogg et al., 1997; Schmidt et al., 2000) . The c-myc promoter contains multiple MREs and transactivation of the c-myc promoter by c-Myb in transient transfections is dependent on both the MREs in the c-myc promoter and the c-Myb DNA-binding domain (Cogswell et al., 1993; Nakagoshi et al., 1992; Zobel et al., 1992) . Recently, Schmidt et al. (2000) used a conditionally active c-Myb-estrogen receptor fusion protein (MybER) to produce stable transfectants in a myeloblastic cell line. Activation of the MybER both prevented the growth arrest induced by interleukin-6 (IL-6) and rapidly restored c-Myc expression in nearly terminally dierentiated cells that had been exposed to IL-6 for 3 days. This report provided direct evidence that the endogenous c-myc locus can be a direct target of c-Myb activity in some cell systems. Our data also suggests that c-myc is a target of Myb activity in MEL cells.
Dierentiation of C19 MEL cells is accompanied by a shift in the content of c-Myc/Max/Mad1 complex from predominantly c-Myc/Max containing complexes to Mad1/Max complexes (Cultraro et al., 1997) . This shift appears to result in part from decreased expression of c-myc in dierentiating MEL cells but also results from an increase in Mad1 expression. Interestingly, forced expression of Mad1 in C19 MEL cells appeared to be sucient to induce terminal dierentiation. Our results show that after induction of MEnT expression, c-Myc expression decreases and there is an accompanying increase in Mad1 expression, resulting in a shift from c-Myc/ Max to Mad/Max containing complexes that is associated with dierentiation in MEL cells. Thus, the regulation of Mad1 expression appears to lie downstream of a pathway that is regulated by Myb activity in MEL cells. However, despite the increased expression of Mad1 in the presence of MEnT, Mad1 is not likely to be a direct target of Myb activity in C19 MEL cells. Instead, it is likely that Myb activity is required for the expression of another gene that regulates expression of transcription from the Mad1 promoter. It will be of considerable interest to identify the cis acting sequences that mediate the increased expression of Mad1 mRNA in the presence of MEnT.
In summary, we have produced stable C19 transfectants that carry a strong dominant interfering myb allele (MEnT) under the control of an inducible mouse metallothionein I promoter. Induction of MEnT expression provides a sucient signal to induce dierentiation in C19 MEL cells. Thus, a pathway controlled by Myb activity is limiting for dierentiation in C19 MEL cells and maintains these cells in an undierentiated and proliferating state. We believe that these cells will provide a useful system to identify physiologically relevant Myb target genes.
Materials and methods
Plasmids
The pUC.MEnT and pSCD.EnT constructs were gifts from Kathleen Weston (Institute of Cancer Research, UK). pUC.MEnT encodes a dominant interfering Myb allele that is a fusion protein containing the six gag codons of AMV vmyb upstream of a truncated murine c-Myb DNA binding domain followed by amino acids 2 ± 298 of the Drosophila engrailed gene a human c-Myc epitope tag (Badiani et al., 1994) . The pSCD.EnT encodes a protein that lacks the cMyb DNA-binding domain but contains amino acids 2 ± 298 of the engrailed protein and a human c-Myc epitope tag. To build vectors for inducible MEnT and EnT expression, cDNAs encoding these proteins were subcloned into the pMTH.neo vector (McClinton et al., 1990) . The pMTH.neo vector contains (i) a mouse metallothionein I (MTH-I) promoter, (ii) a genomic DNA segment encoding the 3' end of exon 2, intron 2, exon 3 and 3'¯anking segments of the human b-globin gene, and (iii) a neomycin expression cassette that serves as a selectable marker. Expression directed from the MTH-I promoter can be induced by ZnCl 2 at 100 mM. MEnT was excised from pUC.MEnT after digestion with BamHI and subcloned into the BamHI site of the pMTH.neo vector, the resulting vector was named pMTH.MEnT. The EnT fragment was obtained by digesting the pSCD.EnT plasmid with XbaI, made blunt-end with the Klenow fragment of DNA polymerase I and inserted into the SrfI site of pMTH.neo. The resulting vector was named pMTH.EnT.
Cell culture and stable transfections
The C19 MEL cell line is a thymidine kinase negative subclone of the 745 murine erythroleukemia cell line (McClinton et al., 1990) and was grown in Roswell Park Memorial Institute (RPMI)-1640 medium supplemented with 10% fetal bovine serum and 2 mM glutamine (growth medium). Stable transfections into C19 MEL cells were performed using lipofectin (Gibco BRL) and neomycin resistant cells were selected in growth medium supplemented with 400 mg/ml G418 as we have previously described (McClinton et al., 1990) . Clones were selected for further study based on inducible expression of the transfected genes (see Figure 1) and subsequently subcloned by limiting dilution in 96-well microtiter plates prior to detailed analysis.
Protein immunoblotting
C19 MEL cells and MEnT stable transfectants were cultured with or without HMBA or ZnCl 2 as indicated, sonicated in 1 ml YRIPA lysis buer (12 mM Na 2 PO 4 , 4 mM NaH 2 PO4, 1% (vol/vol) Nonidet P-40, 1% (wt/vol) sodium deoxycholate, 0.1% (wt/vol) SDS, 2 mM EDTA, pH 8, 1.5 mM EGTA, 150 mM NaCl, 20 mM NaF, 50 mM b-glycerophosphate, 100 mM microcystin, 1 mM Na 3 VO 4 , 1 mM phenylmethylsulfonyl¯uoride with leupeptin at 10 mg/ml, aprotinin at 0.1 unit/ml, and a 2 -macroglobulin at 0.01 unit/ml) and cell debris removed by centrifugation (Aziz et al., 1995) . Protein concentration was assayed using the BCA protein assay (Pierce). One hundred micrograms of whole cell lysate was fractionated by sodium dodecylsulfate-10% polyacrylamide gel electrophoresis (SDS ± PAGE) and the proteins were electrophoretically transferred to nitrocellulose membranes. The membranes were blocked for 1 h in phosphate-buered saline with 0.05% Tween 20 (PBS-T) containing 3% (wt/vol) milk powder as a blocking agent. Speci®c primary antibodies directed against either the human c-Myc epitope tag (0.1 mg/ ml 9E10 mAb, Santa Cruz Biotechnology, Inc), mouse c-Myc (rabbit polyclonal antibody diluted 1 : 1000, Upstate Biotechnology, Inc), mouse Max (rabbit polyclonal antibody diluted 1 : 1000, Upstate Biotechnology, Inc.), mouse Mad-1 (rabbit polyclonal antibody diluted 1 : 1000, Santa Cruz Biotechnology, Inc) or c-Myb (mAb 5e, the kind gift of Dr Eric Westin) were incubated overnight at 48C in PBS containing 3% milk powder. After washing in PBS-T, the membranes were incubated with horseradish peroxidase (HRP)-linked antimouse or anti-rabbit secondary antibody in PBS-T buer supplemented with 3% milk powder. The membranes were washed in PBS-T and immunoreactive species were detected by enhanced chemiluminescence (Amersham).
Coimmunoprecipitation
Cells were lysed as described above and aliquots (1.0 mg) of protein lysates were incubated with 6 mg of anti-Max polyclonal antibody (Upstate Biotechnology, Inc.) and rotated for 1 h at 48C. Fifty microliters of Protein-G sepharose beads (Santa Cruz Biotechnology, Inc) was added, and the incubation was continued overnight. Immunecomplexes were collected by brief centrifugation and washed extensively with YRIPA buer four times. Bound proteins were fractionated on 10% SDS ± PAGE gels and transferred to nitrocellulose membranes for immunoblotting as described above.
Differentiation assays
Dierentiation of C19 MEL cells and stable transfectants was assayed by acid benzidine staining to measure hemoglobin producing cells (Friend et al., 1971) . Brie¯y, cells were plated at a density of 1610 5 cells/ml and grown in the absence or presence of 100 mM ZnCl 2 (stable transfectants) or 3 mM HMBA (C19 MEL parental cells) for 6 days. Cells were maintained in logarithmic phase by daily 1 : 1 dilution with fresh medium. At speci®c time points, cells were removed and stained with acid-benzidine.
Proliferation assay and flow cytometry to measure DNA content Each cell line was plated at a density of 1610 5 /ml and grown in the absence or presence of 100 mM ZnCl 2 (stable transfectants) or 3 mM HMBA (C19 MEL parental cells) for 6 days. Cell numbers from each sample were counted at the indicated time points and cell density was maintained at approximately 1610 5 cells/ml throughout the experiment. For analysis of DNA content, 1610 6 cells at each time point were harvested and washed twice in PBS and cell pellets were stored at 7808C. The cells were resuspended at a density of 2610 6 cells/ml in staining solution which contains 0.1% sodium citrate, 0.3% NP-40, 100 mg/ml propidium iodide and 2 mg/ml RNase A followed by incubation in the dark for 30 min at room temperature. Flow cytometry was performed on a Becton Dickinson FACSCaliber and data were analysed using CELL FIT software (Becton Dickinson).
RNA extraction and Northern blot analysis
C19 MEL cells and MEnT stable transfectants were cultured with or without HMBA and ZnCl 2 as described above. Approximately 10 7 cells were harvested at each time point indicated and total cellular RNA was isolated using RNeasy kits (Qiagen). Ten micrograms of total cellular RNA from each sample was fractionated on 0.8% agarose-formaldehyde gels, transferred to nitrocellulose ®lters and hybridized to [a- 32 P]dCTP nick-translated probes as we have previously described . The probes used were a 600 bp BamHI/EcoRI murine c-myb cDNA fragment encoding the DNA binding domain ), a 1.5 kb XhoI murine c-myc second and third exon cDNA fragment (Stanton et al., 1983) , a 9.6 kb EcoRI fragment of murine a-globin cDNA (McClinton et al., 1990) , a 1.2 kb PstI fragment of chicken glyceraldehydes 3-phosphate dehydrogenase (GAPHD) cDNA (Dugaiczyk et al., 1983) , and a 900 bp Nco1/Sst murine mad1 cDNA fragment (the kind gift of Dr Shoshana Segal, National Cancer Institute). The ®lters were washed and processed for autoradiography as previously described .
